Panacea Venture

Portfolio Companies 2026 for Panacea Venture: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Panacea Venture accounts for 10 tracked companies with verified cap-table data, 10 of which disclose round sizes totalling $1.3B. The median disclosed raise is $60M, and the largest is Multi Investment Holding SA at $616M, ahead of Chime Biologics ($190M) and VelaVigo ($160M).

The names that recur most often on these portfolio cap tables are Panacea Venture (10 companies), Viva BioInnovator (3 companies), CTI Life Sciences (2 companies), 3B Future Health Fund (2 companies), adMare BioInnovations (2 companies), Schroders Capital (2 companies). By latest disclosed round, the market skews Series A (6), Growth (1), Pre-A (1), Series C (1).

Best funded Panacea Venture companies

  1. Multi Investment Holding SA — $616M (latest: Growth)
  2. Chime Biologics — $190M (latest: Series A)
  3. VelaVigo — $160M (latest: Pre-A)
  4. Actym Therapeutics, Inc. — $60M (latest: Series A)
  5. TriArm Therapeutics — $60M (latest: Series A)
  6. XW Laboratories — $58M (latest: Series C)
  7. Domain Therapeutics — $53M (latest: Series A)
  8. hC Bioscience — $40M (latest: Series A)
  9. Inmagene Biopharmaceuticals — $40M (latest: Series B)
  10. GT Apeiron Therapeutics — $18M (latest: Series A)

Panacea Venture — related firms and companies (53)

Panacea Venture alternatives · All research reports